key: cord-1001343-yvw7dqoi
authors: Mandal, M; Mazza, M; Esquinas, A M
title: High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
date: 2022-05-07
journal: Infect Dis Now
DOI: 10.1016/j.idnow.2022.04.008
sha: f48eafc8a2395b6fc2d1025085804a9a85ed6958
doc_id: 1001343
cord_uid: yvw7dqoi

nan

First, age and comorbidities were already found to be independently associated with higher risk of poor outcomes [2] , but in the study by Ouissa R et al. the higher mean age in the 'without tocilizumab' group compared with the 'tocilizumab treatment' group (61 vs 53, respectively) could be a confounding factor for higher percentage of HFNO failure. We therefore think this needs further explanation.

Second, while analyzing the outcome of COVID-19 pneumonia patients, it would have been better to have information about certain indexes which can predict effectiveness of HFNO therapy such as PaO2/FiO2 ratios (mild/moderate/severe), ROX index [3, 4] , and modified ROX index (mROX) by incorporating the heart rate (ROX-HR) [5] and HACOR score [4, 5] . Use of these scores can detect the subset of patients with severe pneumonia for whom tocilizumab would have more benefits, and consequently set a Fourth, it would have been interesting to clarify the causes of HFNO failure and to show whether they used, as alternatives to HFNO, non-invasive or invasive mechanical ventilation. This aspect would allow for a better practical recommendation [6, 7] .

Further clinical trials are needed to define the best cut-off based on an appropriate respiratory score, for the use of HFNO and of tocilizumab.

Successful high flow nasal cannula therapy for severe COVID-19 pneumonia is associated with tocilizumab use

When Conventional Oxygen Therapy Fails-The Effectiveness of High-Flow Nasal Oxygen Therapy in Patients with

Validation of Respiratory Rate-Oxygenation Index in Patients With COVID-19-Related Respiratory Failure

Comparison of ROX and HACOR scales to predict high-flow nasal cannula failure in patients with SARS-CoV-2 pneumonia

Predictors of Helmet CPAP Failure in COVID-19 Pneumonia: A Prospective, Multicenter, and Observational Cohort Study

HNF Hospital Tocilizumab Multidisciplinary Team. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials

HNF Hospital tocilizumab multidisciplinary team. Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia